We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
She joins Enveda from Gilead Sciences
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Subscribe To Our Newsletter & Stay Updated